By contrast, another anti-CD38 monoclonal antibody, isatuximab, relies mainly on antibody-dependent (natural killer cells) cytotoxicity to destroy MM cells, implying that isatuximab treatment may be less affected by resistance mediated by CD55 overexpression [23]. This evidence concerns the gene CD38 and Miyoshi myopathy.